Sign In
Buy GBT
$68.49
+0 (+0%)
At Close: Jan 27, 2023
GBT Announces New Employment Inducement Grants
08:00am, Friday, 09'th Jul 2021
SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on July 1, 2021, the compensation committee of GBT's board of
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation
GBT Announces New Employment Inducement Grants
08:00am, Friday, 04'th Jun 2021
SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on June 1, 2021, the compensation committee of GBT's board of
GBT Announces Upcoming Data Presentations at European Hematology Association (EHA) 2021 Virtual Congress
10:00am, Wednesday, 12'th May 2021
New Oxbryta® (voxelotor) Data from Phase 2a HOPE-KIDS 1 Study Demonstrate Improvement in Hemoglobin and Hemolysis in Children Ages 4 to 11 Years with Sickle Cell Disease New Oxbryta® (voxelotor) Dat
Global Blood Therapeutics: Increasing Specialization In SCD
02:25pm, Sunday, 09'th May 2021
Beyond the initial approval, the company is seeking Oxbryta label expansion as well as approval in the European Union. The company is increasing its focus on sickle cell disease by advancing inclacuma
Global Blood Therapeutics Q1 Earnings Miss Estimates On Disappointing Sales For Its Sickle-Cell Disease Drug
03:03pm, Thursday, 06'th May 2021
Global Blood Therapeutics Inc (NASDAQ: GBT) reported a Q1 EPS loss of ($1.21) wider than the anticipated loss estimate of $1.01. Q1 sales of $39.04 million well below the consensus of $43.00 milli
Why Global Blood Therapeutics Stock Is Sinking Today
11:29am, Thursday, 06'th May 2021
The company reported disappointing sales for its sickle-cell disease drug.
Global Blood Therapeutics, Inc. (GBT) CEO Dr. Ted Love on Q1 2021 Results - Earnings Call Transcript
10:09pm, Wednesday, 05'th May 2021
Global Blood Therapeutics, Inc. (GBT) CEO Dr. Ted Love on Q1 2021 Results - Earnings Call Transcript
Global Blood Therapeutics (GBT) Reports Q1 Loss, Lags Revenue Estimates
06:25pm, Wednesday, 05'th May 2021
Global Blood (GBT) delivered earnings and revenue surprises of -18.63% and -8.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
GBT Reports First Quarter 2021 Financial Results
04:05pm, Wednesday, 05'th May 2021
Achieved Oxbryta ® (voxelotor) net revenues of $39.0 million; on track with plans to potentially expand access to Oxbryta in the U.S. and Europe
NovoCure, Synchrony, Twitter, Yum! and More Wednesday Afternoon Analyst Calls
11:52am, Wednesday, 14'th Apr 2021
With the trading day about halfway over, the broad markets were again somewhat mixed.
Global Blood Therapeutics' Sickle Cell Med Results In Rapid, Durable Improvements In Hemoglobin Levels Throughout 72 Weeks Of Treatment
07:20am, Thursday, 08'th Apr 2021
Global Blood Therapeutics Inc (NASDAQ: GBT) has announced The Lancet Haematology has published the complete analysis of 72-week data from the Phase 3 HOPE Study evaluating Oxbryta (voxelotor) tabl
SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced The Lancet Haematology has published the complete analysis of 72-wee
GBT In-Licenses Two Sickle Cell Disease Programs From Sanofi
09:19am, Tuesday, 16'th Mar 2021
Global Blood Therapeutics Inc (NASDAQ: GBT) has exclusively in-licensed worldwide rights to two early-stage research programs in sickle cell disease from Sanofi SA (NASDAQ: SNY). One program pu
